期刊文献+

来曲唑与三苯氧胺对人卵巢癌顺铂耐药细胞株SKOV3/DDP生长及耐药的影响 被引量:2

Effects of letrozole and tamoxifen on the growth and drug resistance of cisplatin-resistant human ovarian cancer cell line SKOV3/DDP
原文传递
导出
摘要 目的:研究来曲唑(letrozole,LTZ)与三苯氧胺(tamoxifen,TAM)对人卵巢癌顺铂耐药细胞株SKOV3/DDP生长及耐药的影响。方法:采用四甲基偶氮唑蓝(MTT)法,比较不同浓度的LTZ、TAM、LTZ+TAM对SKOV3/DDP细胞生长及对顺铂(cisplatin,DDP)耐药的逆转作用。结果:①不同浓度(1×10-9mol/L~1×10-4mol/L)LTZ或低浓度(1×10-9mol/L~1×10-7mol/L)TAM对SKOV3/DDP细胞生长无抑制,不能逆转DDP引发的耐药。高浓度(1×10-6mol/L~1×10-4mol/L)TAM能抑制SKOV3/DDP细胞的生长且能逆转DDP引发的耐药,与对照组比较,差异有统计学意义(P<0.05)。②1×10-6mol/L TAM与各浓度(1×10-9mol/L~1×10-4mol/L)LTZ联合用药,对该细胞的生长抑制作用及逆转DDP引发的耐药较单用1×10-6mol/L TAM无明显增强,差异无统计学意义(P>0.05);(1×10-5mol/L~1×10-4mol/L)TAM与各浓度(1×10-9 mol/L~1×10-4 mol/L)LTZ联合用药,在LTZ为(1×10-6 mol/L~1×10-4 mol/L)时,两药联合对该细胞的生长抑制作用与单用TAM(1×10-5mol/L~1×10-4mol/L)及组间相比差异有统计学意义(P<0.01);在LTZ为(1×10-5mol/L~1×10-4mol/L)时,两药联合逆转DDP引发的耐药与单用TAM(1×10-5mol/L~1×10-4mol/L)逆转及组间相比,差异有统计学意义(P<0.01)。结论:高浓度TAM可以逆转SKOV3/DDP细胞对DDP的耐药性;高浓度LTZ与TAM联合可使TAM逆转SK-OV3/DDP细胞对DDP耐药的作用增强。 Objective:To study the effects of letrozole and tamoxifen on the growth and drug resistance of cisplatin-resistant human ovarian cancer cell line SKOV3/DDP.Methods:MTT method was used to compare the reversal effects of different concentrations of letrozole,tamoxifen,and letrozole plus tamoxifen on the growth and drug resistance of cisplatin-resistant human ovarian cancer cell line SKOV3/DDP.Results:Different concentrations(1×10^-9 mol/L-1×10^-4 mol/L) of letrozole and low concentration tamoxifen had no impact on the growth of SKOV3/DDP cells,which couldn't reverse drug resistance to DDP.High concentration(1×10^-6 mol/L-1×10^-4 mol/L) tamoxifen could repress the growth of SKOV3/DDP cells and reverse drug resistance to DDP,compared with control group,there was significant difference(P〈0.05).There was no significant difference in the inhibiting effect on the growth of SKOV3/DDP cells and the reversal effect on drug resistance to DDP between combined application of 1×10^-6mol/L tamoxifen and different concentrations(1×10^-9 mol/L-1×10^-4 mol/L) of letrozole and simple application of 1×10^-6mol/L tamoxifen(P〈0.05).There was significant difference in the inhibiting effect on the growth of SKOV3/DDP cells between combined application of letrozole(1×10^-6 mol/L-1×10^-4 mol/L) and tamoxifen(1×10^-5 mol/L-1×10^-4 mol/L) and simple application of tamoxifen(1×10^-5 mol/L-1×10^-4 mol/L)(P〈0.01).There was significant difference in the reversal effect on drug resistance to DDP between combined application of letrozole(1×10^-5 mol/L-1×10^-4 mol/L) and tamoxifen(1×10^-5 mol/L-1×10^-4 mol/L) and simple application of tamoxifen(1×10^-5 mol/L-1×10^-4 mol/L)(P〈0.01).Conclusion:High concentration tamoxifen can reverse the drug resistance of SKOV3/DDP cells to DDP,high concentration letrozole combined with tamoxifen can enhance the reversal effect of tamoxifen on drug resistance to DDP.
作者 高翠红 韩萍
出处 《中国妇幼保健》 CAS 北大核心 2012年第13期2013-2017,共5页 Maternal and Child Health Care of China
基金 河北省2010年医学科学研究重点课题计划〔20100132〕
关键词 卵巢癌 来曲唑 三苯氧胺 耐药逆转 雌激素受体 Ovarian cancer Letrozole Tamoxifen Drug resistance reversal Estrogen receptor
  • 相关文献

参考文献11

  • 1朱婷,汪希鹏,马庆良.芳香化酶抑制剂治疗妇科恶性肿瘤进展[J].国际妇产科学杂志,2008,35(5):341-344. 被引量:5
  • 2王甜甜,吕秀萍.来曲唑在临床中的应用研究[J].医学综述,2008,14(6):922-925. 被引量:6
  • 3Smyth JF,Gourley C,Walker G et al.Antiestrogen therapy is active in selected ovarian cancer cases:the use of letrozole in estrogen receptor-positive patients[J].Clin Cancer Res,2007,13(12):3617-3622.
  • 4Bowman A,Gabra H,Langdon SP et al.CA125 response is associated with estrogen receptor expression in a phaseⅡtrial of letrozole in ovarian cancer:identification of an endocrine-sensitive subgroup[J].Clin Cancer Res,2002,8(7):2233-2239.
  • 5Cunat S,Rabenoelina F,Daures JP et al.Aromatase expres-sion in ovarian epithelial cancer[J].J Steroid Biochem MolBiol,2005,93(1):15-24.
  • 6冯婷,柴芸,周坚红.P450Arom、雌激素受体α在浆液性卵巢癌中的表达[J].肿瘤学杂志,2010,16(7):569-571. 被引量:5
  • 7Bell DA.Origins and molecular pathology of ovarian cancer[J].Modern Pathology,2005,18:s19-s32.
  • 8Marta Keith Bechtel,Benjamin Bonavida.Inhibitory effects of17β-estradiol and progesterone on ovarian carcinoma cell pro-liferation:a potential role for inducible nitric oxide synthase[J].Gynecologic Oncology,2001,82(1):127-138.
  • 9Lucia MB,Golotta C,Rutella S et al.Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity[J].J Acquir Immune Defic Syndr,2005,39(5):635-637.
  • 10石小鹏,郭晓彤,杨春娥.三苯氧胺逆转肿瘤耐药作用的研究进展[J].中国药房,2006,17(18):1422-1423. 被引量:1

二级参考文献58

  • 1王进,黄守松,冯忻.三苯氧胺逆转卵巢癌细胞株多药耐药性的研究[J].国际医药卫生导报,2005,11(16):6-8. 被引量:3
  • 2陈日新,廖勇,逯华,伍美娟.大剂量三苯氧胺逆转治疗对NP方案耐药的晚期非小细胞肺癌的临床观察[J].华夏医学,2005,18(4):522-524. 被引量:1
  • 3洪专,郑秀立.恶性肿瘤对抗癌药物的耐药问题[J].实用临床医药杂志,2005,9(11):2-7. 被引量:7
  • 4马晓欣,张淑兰,高山,陆景明,董芳.芳香化酶蛋白及性激素受体等在子宫内膜病变组织中的表达变化及意义[J].中华妇产科杂志,2006,41(6):395-398. 被引量:6
  • 5[1]Cunat S,Rabenoelina F,Daures JP,et al.Aromatase expression in ovarian epithelial cancers[J].J Steroid Biochem Mol Biol,2005,93(1):15-24.
  • 6[2]Carmen MG,Fuller AF,Matulonis U,et al.Phase Ⅱ trial of anastrozole in women with asymptomatic müllerian cancer[J].Gynecol Oncol,2003,91 (3):596-602.
  • 7[3]Lee E J,Deavers MT,Hughes JI,et al.Metastasis to sigmoid colon mucosa and submucosa from serous borderline ovarian tumor.response to hormone therapy[J].Int J Gynecol Caner,2006,16[Suppl 1]:295-299.
  • 8[4]Smyth JF,Gourley C,Walker G,et al.Antiestrogen therapy is active in selected ovarian cancer cases:the use of letrozole in estrogen receptor-positive patients[J].Clin Cancer Res,2007,13 (12):3617-3622.
  • 9[5]Bowman A,Gabra H,Langdon SP,et al.CA125 response is associated with estrogen receptor expression in a phase Ⅱ trial of letrozole in ovarian cancer,identification of an endocrine-sensitive subgroup[J].Clin Cancer Res,2002,8 (7):2233-2239.
  • 10[6]Matsumoto M,Yamaguchi Y,Seino Y,etal.Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction[J].Endocr Relat Cancer,2008,15 (2):451-463.

共引文献18

同被引文献15

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部